These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 31490101)
1. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation. Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101 [TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and QM/MM calculation reveal the selectivity mechanism of type I 1/2 kinase inhibitors: the effect of intramolecular H-bonds and conformational restriction for improved selectivity. Wang H; Gao Z; Song P; Hu B; Wang J; Cheng M Phys Chem Chem Phys; 2019 Nov; 21(43):24147-24164. PubMed ID: 31657381 [TBL] [Abstract][Full Text] [Related]
3. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors. Han D; Wang H; Cui W; Zhang B; Chen BZ Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922 [No Abstract] [Full Text] [Related]
4. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation. Gao Y; Wang H; Wang J; Cheng M J Biomol Struct Dyn; 2020 Sep; 38(14):4119-4133. PubMed ID: 31556340 [TBL] [Abstract][Full Text] [Related]
5. P21 activated kinase signaling in cancer. Rane CK; Minden A Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094 [TBL] [Abstract][Full Text] [Related]
6. The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences. Sun X; Su VL; Calderwood DA J Biol Chem; 2019 Sep; 294(39):14319-14332. PubMed ID: 31391252 [TBL] [Abstract][Full Text] [Related]
7. A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1). Shahinozzaman M; Ishii T; Ahmed S; Halim MA; Tawata S J Biomol Struct Dyn; 2020 Aug; 38(12):3514-3526. PubMed ID: 31448698 [TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors. Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083 [TBL] [Abstract][Full Text] [Related]
9. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors. Gul M; Fakhar M; Najumuddin ; Rashid S PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805 [TBL] [Abstract][Full Text] [Related]
10. p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation. Siu MK; Kong DS; Ngai SY; Chan HY; Jiang L; Wong ES; Liu SS; Chan KK; Ngan HY; Cheung AN PLoS One; 2015; 10(7):e0133467. PubMed ID: 26218748 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of p21-activated kinases (PAKs). Rudolph J; Crawford JJ; Hoeflich KP; Wang W J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Tabusa H; Brooks T; Massey AJ Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484 [TBL] [Abstract][Full Text] [Related]
13. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity. Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553 [TBL] [Abstract][Full Text] [Related]
14. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation. Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728 [TBL] [Abstract][Full Text] [Related]
15. Determination of potential selective inhibitors for ROCKI and ROCKII isoforms with molecular modeling techniques: structure based docking, ADMET and molecular dynamics simulation. Bayel Secinti B; Tatar G; Taskin Tok T J Biomol Struct Dyn; 2019 Jun; 37(9):2457-2463. PubMed ID: 30047850 [TBL] [Abstract][Full Text] [Related]
16. Rho family GTPase signaling through type II p21-activated kinases. Chetty AK; Ha BH; Boggon TJ Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658 [TBL] [Abstract][Full Text] [Related]
17. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer. Shao YG; Ning K; Li F World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660 [TBL] [Abstract][Full Text] [Related]
18. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach. Agarwal S; Kashaw SK J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248 [TBL] [Abstract][Full Text] [Related]
19. Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1. Shahinozzaman M; Ahmed S; Emran R; Tawata S Sci Rep; 2021 Sep; 11(1):17471. PubMed ID: 34471161 [TBL] [Abstract][Full Text] [Related]